持续乙酰水杨酸治疗不影响动脉瘤性蛛网膜下腔出血的出血模式或结局:一项配对分析
该配对分析纳入1999年6月至2014年12月在本机构治疗的1422例动脉瘤性SAH患者,其中144例(10.1%)在动脉瘤破裂时持续使用ASA。ASA组患者年龄显著大于非ASA组(60岁 vs 53岁,P<0.001),但入院状态、出血模式及微创或血管内操作的治疗相关并发症率均无显著差异,配对分析中结局无差异。因此,ASA使用不应影响破裂动脉瘤的治疗决策。
要点
- 持续ASA治疗的患者年龄显著大于非ASA患者(60岁 vs 53岁,P<0.001)。
- ASA组动脉瘤再出血率4.7% vs 非ASA组2.3%(P=0.3),差异未达统计学显著。
- 配对分析中ASA组与非ASA组良好结局(mRS 0-2)分别为49.3% vs 52.1%(P=0.7),无显著差异。
核心结论
- 持续ASA治疗的患者年龄显著大于非ASA患者,但入院状态或出血模式无差异,配对分析中结局无差异,微创与血管内操作的治疗相关并发症率无统计学差异,因此ASA使用不应影响破裂动脉瘤的治疗决策。
研究设计与样本
- 配对分析,纳入1999年6月至2014年12月在本机构治疗的1422例动脉瘤性SAH患者,其中144例(10.1%)在动脉瘤破裂时持续使用ASA。
主要发现
- 动脉瘤破裂时持续使用ASA的患者比例显著上升(P<0.01)。
- ASA组患者年龄显著大于非ASA组(60岁 vs 53岁,P<0.001)。
- ASA组动脉瘤再出血率4.7% vs 非ASA组2.3%(P=0.3),差异未达统计学显著。
- ASA组治疗相关出血并发症率13.9% vs 非ASA组6.2%(P=0.06),差异未达统计学显著。
- 微创或血管内操作中治疗相关并发症率ASA组16.4% vs 非ASA组12.2%(P=0.6),无显著差异。
临床怎么用
- 原文结论指出,ASA使用不应影响破裂动脉瘤的治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Demographic changes are leading to an aging society with a growing number of patients with cardiovascular diseases, relying on antiplatelet drugs like acetylsalicylic acid (ASA). Although antiplatelet agents are suspected to be protective not only in the cardiologic but in the neurovascular field, the alteration of the coagulating process could have a major impact on the course and outcome after rupture of intracranial aneurysms. METHODS: Between June 1999 and December 2014, 1422 patients were treated for aneurysmal SAH in our institution, 144 (10.1%) with continuous ASA at the time of aneurysm rupture. A matched-pair analysis was performed. RESULTS: The rate of patients with continuous ASA treatment while rupture of the aneurysm is rising significantly (P < 0.01). Those patients were significantly older than patients without ASA (60 vs. 53 years, P < 0.001). ASA-treated patients more often had aneurysmal rebleeding (4.7% vs. 2.3%, P = 0.3) and treatment-related hemorrhagic complications (13.9% vs. 6.2%, P = 0.06). However, rates were not different in microsurgical or endovascular procedures (16.4% vs. 12.2%, P = 0.6). Favorable outcome (Modified Rankin Scale 0-2) was achieved in 49.3% of the ASA group and 52.1% of the control group (P = 0.7). CONCLUSION: Patients with continuous ASA treatment were significantly older than patients without ASA, but there was no difference in admission status or bleeding pattern. Outcome was not different in the matched-pair analysis. There was no statistical difference in treatment related-complication rates of microsurgical and endovascular procedures. Therefore, ASA use should not influence treatment decision of the ruptured aneurysm.
引用
- Bruder M, Won SY, Wagner M, et al. Continuous Acetylsalicylic Acid Treatment Does Not Influence Bleeding Pattern or Outcome of Aneurysmal Subarachnoid Hemorrhage: A Matched-Pair Analysis. World Neurosurg. 2018. PMID: 29408591. doi:10.1016/j.wneu.2018.01.188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。